Monopar Therapeutics Inc.
MNPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $13,006 | $5,600 | $7,592 | $6,493 |
| G&A Expenses | $3,156 | $3,231 | $2,945 | $2,634 |
| SG&A Expenses | $3,156 | $3,231 | $2,945 | $2,634 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16,162 | $8,831 | $10,537 | $9,127 |
| Operating Income | -$16,162 | -$8,831 | -$10,537 | -$9,127 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $575 | $429 | $21 | $24 |
| Pre-Tax Income | -$15,586 | -$8,402 | -$10,516 | -$9,103 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15,586 | -$8,402 | -$10,516 | -$9,103 |
| % Margin | – | – | – | – |
| EPS | -1.36 | -0.58 | -0.83 | -0.73 |
| % Growth | -134.5% | 30.1% | -13.7% | – |
| EPS Diluted | -1.36 | -0.58 | -0.83 | -0.73 |
| Weighted Avg Shares Out | 11,444 | 14,511 | 12,718 | 12,472 |
| Weighted Avg Shares Out Dil | 11,484 | 14,511 | 12,718 | 12,472 |
| Supplemental Information | – | – | – | – |
| Interest Income | $404 | $429 | $21 | $24 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16,162 | -$8,831 | -$10,537 | -$9,127 |
| % Margin | – | – | – | – |